Arcus Biosciences (RCUS) Competitors

Arcus Biosciences (NYSE:RCUS) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Do analysts prefer RCUS or AKRO?

Arcus Biosciences presently has a consensus price target of $28.38, suggesting a potential upside of 249.45%. Akero Therapeutics has a consensus price target of $76.29, suggesting a potential upside of 92.42%. Given Arcus Biosciences' higher possible upside, equities analysts plainly believe Arcus Biosciences is more favorable than Akero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.00
Akero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals & insiders hold more shares of RCUS or AKRO?

92.9% of Arcus Biosciences shares are owned by institutional investors. 12.3% of Arcus Biosciences shares are owned by insiders. Comparatively, 7.9% of Akero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Is RCUS or AKRO more profitable?

Akero Therapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -102.66%. Akero Therapeutics' return on equity of -32.46% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-102.66%	-45.59%	-22.38%
Akero Therapeutics	N/A	-32.46%	-29.83%

Does the media favor RCUS or AKRO?

In the previous week, Arcus Biosciences and Arcus Biosciences both had 6 articles in the media. Akero Therapeutics' average media sentiment score of 1.04 beat Arcus Biosciences' score of 0.68 indicating that Akero Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akero Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger valuation and earnings, RCUS or AKRO?

Akero Therapeutics has lower revenue, but higher earnings than Arcus Biosciences. Akero Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$258M	3.31	-$307M	-$3.10	-2.62
Akero Therapeutics	N/A	N/A	-$151.76M	-$3.75	-10.57

Does the MarketBeat Community believe in RCUS or AKRO?

Arcus Biosciences received 80 more outperform votes than Akero Therapeutics when rated by MarketBeat users. Likewise, 65.45% of users gave Arcus Biosciences an outperform vote while only 65.36% of users gave Akero Therapeutics an outperform vote.

Company	Underperform	Outperform
Arcus Biosciences	Outperform Votes 197 65.45%	Underperform Votes 104 34.55%
Akero Therapeutics	Outperform Votes 117 65.36%	Underperform Votes 62 34.64%

Which has more volatility & risk, RCUS or AKRO?

Arcus Biosciences has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500.

Summary

Arcus Biosciences beats Akero Therapeutics on 11 of the 16 factors compared between the two stocks.